OKYO Pharma (OKYO) CEO discloses multiple stock option positions

Rhea-AI Filing Summary

OKYO Pharma Ltd filed a Form 3 showing that Chief Executive Officer Robert John Dempsey holds four stock option positions over its common stock. Each option position relates to 400,000 shares of common stock at an exercise price of $2.2300 per share.

The options have staggered exercise dates on January 2, 2027, January 2, 2028, January 2, 2029, and January 2, 2030, and all are scheduled to expire on January 2, 2036. The filing records these as existing holdings rather than new market transactions.

Insider Trade Summary

4 transactions reported

Mixed 4 txns

Insider Dempsey Robert John

Role CHIEF EXECUTIVE OFFICER

Type	Security	Shares	Price	Value
holding	Options	--	--	--
holding	Options	--	--	--
holding	Options	--	--	--
holding	Options	--	--	--

Holdings After Transaction: Options — 400,000 shares (Direct, null)

Footnotes (1)

Key Figures

Option exercise price: $2.2300 per share Underlying shares per option position: 400,000 shares First exercise date: January 2, 2027 +4 more

7 metrics

Option exercise price $2.2300 per share Exercise price for CEO stock options

Underlying shares per option position 400,000 shares Common stock underlying each option holding

First exercise date January 2, 2027 Earliest option exercise date

Second exercise date January 2, 2028 Second option exercise date

Third exercise date January 2, 2029 Third option exercise date

Fourth exercise date January 2, 2030 Fourth option exercise date

Option expiration date January 2, 2036 Expiration for all reported options

Key Terms

Form 3, stock options, underlying security, exercise price, +1 more

5 terms

Form 3 regulatory

"OKYO Pharma Ltd filed a Form 3 showing insider holdings."

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

stock options financial

"The CEO holds four stock option positions over common stock."

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

underlying security financial

"Each option lists common stock as the underlying security."

exercise price financial

"All options share an exercise price of $2.2300 per share."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"The options share a common expiration date in January 2036."

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Dempsey Robert John

(Last) (First) (Middle)

C/O OKYO PHARMA LTD,

14-15 CONDUIT STREET

(Street)

LONDON MASSACHUSETTS W1S 2XJ

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
OKYO Pharma Ltd [ OKYO ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF EXECUTIVE OFFICER

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options	01/02/2027	01/02/2036	Common Stock	400,000	$2.23	D
Options	01/02/2028	01/02/2036	Common Stock	400,000	$2.23	D
Options	01/02/2029	01/02/2036	Common Stock	400,000	$2.23	D
Options	01/02/2030	01/02/2036	Common Stock	400,000	$2.23	D

Explanation of Responses:

	/s/ Robert Dempsey	05/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the OKYO Pharma (OKYO) Form 3 filing show about insider holdings?

The Form 3 shows CEO Robert John Dempsey holds four option positions, each over 400,000 OKYO Pharma common shares at an exercise price of $2.2300, with staggered future exercise dates and a common expiration in 2036.

How many OKYO Pharma shares are covered by Robert Dempsey’s reported options?

Each of the four reported option positions covers 400,000 shares of OKYO Pharma common stock. The filing lists them as separate holdings, all with the same exercise price and expiration but different exercise dates starting in 2027.

What is the exercise price of the OKYO Pharma stock options reported on Form 3?

All four option holdings reported for OKYO Pharma’s CEO have an exercise price of $2.2300 per share. This is the price at which he can buy the underlying common stock if and when the options are exercised in future years.

When do the reported OKYO Pharma options become exercisable and when do they expire?

The options become exercisable on four different dates: January 2, 2027, January 2, 2028, January 2, 2029, and January 2, 2030. All positions are scheduled to expire on January 2, 2036, according to the filing data.

Does the OKYO Pharma Form 3 indicate recent insider buying or selling activity?

The Form 3 records existing option holdings for the CEO rather than new open-market purchases or sales. Transaction fields are classified as holdings with unknown direction, and the transaction summary shows no buy, sell, exercise, gift, or tax-withholding events.